Furkan Uğur

Dr. Furkan Uğur

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Medicina
Verified
Journal Article
Open access
PDF file
BKBahadır Kartal
Bahadır Kartal
MTMehmet Berksun Tutan
Mehmet Berksun Tutan
VTVeysel Barış Turhan
Veysel Barış Turhan
FUFurkan Uğur
Furkan Uğur
EAErtuğrul Gazi Alkurt
Ertuğrul Gazi Alkurt
Background and Objectives: This study aimed to investigate the role of serum sodium levels as an independent predictor of complications in acute diverticulitis and to evaluate their diagnostic value alongside inflammatory markers. Materials and Methods: A total of 134 patients diagnosed with acute diverticulitis between June 2018 and January 2024 at the Erol Olçok Training and Research Hospital were retrospectively analyzed. Complicated diverticulitis was defined based on the presence of an abscess, perforation, fistula, or obstruction classified as Hinchey stage II-IV. Serum sodium, CRP, and WBC levels were assessed for their predictive value. Statistical analyses included ROC analysis to determine optimal thresholds and logistic regression to evaluate independent predictors. Results: A total of 29.1% of the patients were classified as having complicated diverticulitis. Serum sodium levels were significantly lower in the complicated group (median: 133 mmol/L, p < 0.001), whereas CRP (median: 86.5 mg/L, p < 0.001) and WBC levels (median: 11.62 × 103/µL, p = 0.001) were higher. The ROC analysis identified <135.5 mmol/L as the optimal threshold for serum sodium, with a 94.9% sensitivity and 94.7% specificity, making it the strongest predictor. The logistic regression revealed that each unit decrease in serum sodium increased the risk of complications by 5.7 times (p < 0.001). Conclusions: Serum sodium levels are an independent and strong predictor of complications in acute diverticulitis. When used alongside CRP and WBC levels, diagnostic accuracy can be enhanced, leading to improved patient management.

24 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OAOrhan Aslan
Orhan Aslan
RTRamazan Topcu
Ramazan Topcu
ISIsmail Sezikli
Ismail Sezikli
MYMahmut Arif Yüksek
Mahmut Arif Yüksek
APAşkın Kadir Perçem
Aşkın Kadir Perçem
FUFurkan Uğur
Furkan Uğur
Background and Objective: The metastatic lymph node ratio (MLNR) has emerged as a significant prognostic marker in colon cancer (CC). This study evaluated the impact of MLNR on disease-free survival (DFS), overall survival (OS), and recurrence, comparing it to TNM staging. Materials and Methods:A retrospective analysis included CC patients who underwent surgical treatment. The prognostic value of MLNR was analyzed using Kaplan-Meier survival analysis and multivariate regression, alongside clinical factors such as age, tumor localization, and type of surgery. The relationship between MLNR and the efficacy of adjuvant chemotherapy was also investigated. Results:Patients with an MLNR > 0.125 showed a significantly higher risk of disease recurrence (hazard ratio [HR]: 7.0, p< 0.001) and shorter DFS. Kaplan-Meier analysis demonstrated that lower MLNR was associated with significantly longer DFS (p< 0.001). MLNR was found to be an independent prognostic factor, outperforming TNLC in predicting OS and DFS (p< 0.001). Patients receiving adjuvant therapy had a significantly lower risk of disease recurrence compared to those who did not (p=0.015). Multivariate analysis identified adjuvant therapy and MLNR as independent prognostic factors. The reduced recurrence risk observed in patients receiving adjuvant therapy (Exp(B): 0.234, p=0.038) underscores the efficacy of this treatment. Emergency surgery was significantly associated with worse survival (p=0.023). Conclusion:MLNR is a valuable prognostic marker in colon cancer and can complement the TNM staging system to refine survival predictions.Our findings suggest that MLNR can guide adjuvant treatment decisions, supporting more personalized therapeutic approaches.Larger prospective studies are needed to validate the optimal MLNR cut-off value and further assess its clinical utility.